Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 2:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 20,596 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Immune Dysfunction Clear all
Completed No phase listed Observational Accepts healthy volunteers

A Pilot Study to Assess microRNA Biomarkers in Early and Later Stage Multiple Sclerosis

NCT01737372
View directory record Official record
Conditions
Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Clinically Isolated Syndrome
Interventions
Not listed
Lead sponsor
John F. Foley, MD
Other
Eligibility
18 Years to 68 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 9, 2016 · Synced Oct 17, 2026, 2:04 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of VELCADE® With Mitoxantrone and Etoposide for Leukemias

NCT00410423
View directory record Official record
Conditions
Relapsed Acute Leukemia, Refractory Acute Leukemia
Interventions
Bortezomib with mitoxantrone, etoposide and cytarabine, Bortezomib 1.0mg/m^2, Bortezomib 1.3mg/m^2
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Oct 17, 2026, 2:04 PM EDT
Active, not recruiting Phase 2 Interventional

Concurrent Chemotherapy and Radiation Therapy for Newly Diagnosed Nasal NK Cell Lymphoma

NCT02106988
View directory record Official record
Conditions
Lymphoma
Interventions
Radiation Therapy, Dexamethasone, Etoposide phosphate, Ifosfamide, Mesna, Carboplatin
Radiation · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2034
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 17, 2026, 2:04 PM EDT
Not listed Phase 4 Interventional

Evaluation of Belimumab Impact on a BLyS Activity Signature Test in the Absence of Confounding Polypharmacy

NCT02270970
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
belimumab
Biological
Lead sponsor
Oklahoma Medical Research Foundation
Other
Eligibility
16 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Dec 7, 2017 · Synced Oct 17, 2026, 2:04 PM EDT
Completed Phase 2 Interventional

The Role of Cyclosporine in Blood Cell Transplants With T-Cell Add-Back for Blood Cancers

NCT00001873
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Graft vs Host Disease, Hematologic Neoplasm, Multiple Myeloma, Myelodysplastic Syndrome
Interventions
Isolex 300i plus MoAbs
Device
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
10 Years to 55 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 26, 2018 · Synced Oct 17, 2026, 2:04 PM EDT
Recruiting Not applicable Interventional

Assessing the Use of MY-RIDE, a Just-in-time Adaptive Intervention, to Improve HIV Prevention and Substance Use in Youth Experiencing Homelessness

NCT06074354
View directory record Official record
Conditions
HIV Infections
Interventions
Attention-control group, MY-RIDE group
Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 25 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 17, 2026, 2:04 PM EDT
Completed Not applicable Interventional

Sleep Quality in High School Students With Asthma - II

NCT03329066
View directory record Official record
Conditions
Asthma, Sleep, Asthma in Children
Interventions
MAST - Managing Asthma & Sleep in Teens, ASMA - Asthma Self-Management for Adol, Information & Referral Control Group
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
13 Years to 17 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
New York, New York • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Mar 4, 2021 · Synced Oct 17, 2026, 2:04 PM EDT
Completed Phase 1 Interventional

Perifosine in Treating Patients With Refractory Solid Tumors or Hematologic Cancer

NCT00019656
View directory record Official record
Conditions
Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
perifosine
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 29, 2015 · Synced Oct 17, 2026, 2:04 PM EDT
Completed No phase listed Observational

Quality of Life in Children With HIV Infection

NCT00075153
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
10 Months to 25 Years
Enrollment
1,993 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 22, 2014 · Synced Oct 17, 2026, 2:04 PM EDT
Completed Phase 2 Interventional

4'-Iodo-4'-Deoxydoxorubicin in Treating Patients With Primary Systemic Amyloidosis

NCT00003853
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
4'-iodo-4'-deoxydoxorubicin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
2
States / cities
Little Rock, Arkansas • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 12, 2012 · Synced Oct 17, 2026, 2:04 PM EDT
Suspended Phase 1Phase 2 Interventional

Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL

NCT04855253
View directory record Official record
Conditions
DLBCL, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, DLBCL Arising From Follicular Lymphoma
Interventions
E7777, Fludarabine, Cyclophosphamide, Tisagenlecleucel, Axicabtagene Ciloleucel, Lisocabtagene Maraleucel Intravenous Suspension
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Oct 17, 2026, 2:04 PM EDT
Not listed No phase listed Observational

Biomarker Verification in Pediatric Chronic GvHD: ABLE 2.0 / PTCTC GVH 1901 Study

NCT04372524
View directory record Official record
Conditions
Chronic Graft-versus-Host-Disease, Leukemia, Allogeneic Hematopoietic Stem Cell Transplantation, Blood Cancer, Non-Malignant Hematologic and Lymphocytic Disorder
Interventions
Not listed
Lead sponsor
University of British Columbia
Other
Eligibility
0 Years to 24 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
11
States / cities
San Francisco, California • Denver, Colorado • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2023 · Synced Oct 17, 2026, 2:04 PM EDT
Active, not recruiting Phase 2 Interventional

Senolytics Treatment of Interstitial Lung Disease in Common Variable Immunodeficiency

NCT05593588
View directory record Official record
Conditions
Common Variable Immunodeficiency, Interstitial Lung Disease Due to Systemic Disease
Interventions
Fisetin, Placebo
Drug
Lead sponsor
Avni Joshi
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 17, 2026, 2:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Determine the Effect of Multiple Oral Doses of SLx-2119 in Healthy Male Subjects

NCT05918627
View directory record Official record
Conditions
Immune System Disorder (Healthy Volunteer)
Interventions
Belumosudil mesylate, Placebo
Drug
Lead sponsor
Kadmon, a Sanofi Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 26, 2023 · Synced Oct 17, 2026, 2:04 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Within My Reach (WMR) Adaptation

NCT06056661
View directory record Official record
Conditions
Hiv, Violence
Interventions
WMR
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 24, 2024 · Synced Oct 17, 2026, 2:04 PM EDT
Not listed Phase 2 Interventional

A Study of TL-925 for the Treatment of Allergic Conjunctivitis

NCT06153342
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
TL-925, Placebo
Drug
Lead sponsor
Telios Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 1, 2023 · Synced Oct 17, 2026, 2:04 PM EDT
Completed Phase 3 Interventional Results available

Intravenous Immunoglobulin for PANDAS

NCT01281969
View directory record Official record
Conditions
Obsessive-Compulsive Disorder, Children, Anxiety Disorder, Autoimmune Disease, PANDAS
Interventions
Gamunex Intravenous Immunoglobulin, Placebo
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
4 Years to 13 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 17, 2020 · Synced Oct 17, 2026, 2:04 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of CC-220 in Subjects With Active Systemic Lupus Erythematosus

NCT03161483
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
CC-220, Placebo
Drug · Other
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
46
States / cities
Tuscaloosa, Alabama • Mesa, Arizona • Fullerton, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 17, 2026, 2:04 PM EDT
Completed Phase 2 Interventional Results available

Uproleselan (GMI-1271) for GI Toxicity Prophylaxis During Melphalan-Conditioned Autologous Hematopoietic Cell Transplantation (Auto-HCT) for Multiple Myeloma (MM)

NCT04682405
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Uproleselan, Placebo, Melphalan
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 75 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 15, 2023 · Synced Oct 17, 2026, 2:04 PM EDT
Completed No phase listed Observational

Development of Pain Management JITAI Content in Multiple Sclerosis and Spinal Cord Injury

NCT07663266
View directory record Official record
Conditions
Multiple Sclerosis, Spinal Cord Injury
Interventions
Push Notification Content
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 17, 2026, 2:04 PM EDT
Completed No phase listed Observational

Gene-Environment Interactions in Rheumatoid Arthritis Autoimmunity Disease Severity

NCT00594451
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Not listed
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 1, 2023 · Synced Oct 17, 2026, 2:04 PM EDT
Recruiting Not applicable Interventional

Home Hospital for Suddenly Ill Adults

NCT03524222
View directory record Official record
Conditions
Infection, Heart Failure, COPD, Asthma, Gout Flare, Chronic Kidney Diseases, Hypertensive Urgency, Atrial Fibrillation Rapid, Anticoagulants; Increased
Interventions
Home Hospitalization
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2031
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 17, 2026, 2:04 PM EDT
Completed Not applicable Interventional

Registry and Screening Tool to Identify Children With Asthma Likely to Benefit From Home Assessment and Remediation

NCT03916237
View directory record Official record
Conditions
Asthma, Pediatric ALL, School Health Services, Registries, Medical Informatics, Home Visits, Housing Problems, Social Determinants of Health, Healthcare Disparity, Health Status Disparity
Interventions
Home assessment, Home remediation, Referral to Medical Legal Partnership, Regular School Based Health Asthma Care
Other
Lead sponsor
MetroHealth Medical Center
Other
Eligibility
5 Years to 17 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 19, 2023 · Synced Oct 17, 2026, 2:04 PM EDT
Completed Phase 1 Interventional

Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia

NCT00258245
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
ascorbic acid, arsenic trioxide, bortezomib, dexamethasone, thalidomide, Aspirin
Dietary Supplement · Drug
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 29, 2013 · Synced Oct 17, 2026, 2:04 PM EDT